Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martina Bonechi

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast CancerRinath Jeselsohn, William T Barry, Ilenia Migliaccio, et al.
Therapeutic Advances in Medical Oncology|December 20, 2019
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)Emanuela Risi, Chiara Biagioni, Matteo Benelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd TrialAmelia McCartney, Martina Bonechi, Francesca De Luca, et al.
Breast Cancer Research : BCR|March 25, 2021
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialFrancesca Galardi, Francesca De Luca, Chiara Biagioni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
TransCONFIRM: Identification of a Genetic Signature of Response to Fulvestrant in Advanced Hormone Receptor-Positive Breast CancerRinath Jeselsohn, William T Barry, Ilenia Migliaccio, et al.
Therapeutic Advances in Medical Oncology|December 20, 2019
An RB-1 loss of function gene signature as a tool to predict response to neoadjuvant chemotherapy plus anti-HER2 agents: a substudy of the NeoALTTO trial (BIG 1-06)Emanuela Risi, Chiara Biagioni, Matteo Benelli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2020
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd TrialAmelia McCartney, Martina Bonechi, Francesca De Luca, et al.
Breast Cancer Research : BCR|March 25, 2021
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trialFrancesca Galardi, Francesca De Luca, Chiara Biagioni, et al.
European Journal of Cancer (Oxford, England : 1990)|May 7, 2019
Prognostic role of serum thymidine kinase 1 activity in patients with hormone receptor-positive metastatic breast cancer: Analysis of the randomised phase III Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT)Amelia McCartney, Chiara Biagioni, Gaia Schiavon, et al.
Pageof 2